tiprankstipranks
Connect Biopharma Holdings (CNTB)
NASDAQ:CNTB
US Market

Connect Biopharma Holdings (CNTB) Income Statement

41 Followers

Connect Biopharma Holdings Income Statement

Last quarter (Q4 2022), Connect Biopharma Holdings's total revenue was ¥―, a decrease of ― from the same quarter last year. In Q4, Connect Biopharma Holdings's net income was ¥―. See Connect Biopharma Holdings’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 22Dec 21Dec 20Dec 19
Total Revenue
---¥ 0.00¥ 0.00
Cost of Revenue
-¥ -7.99M¥ -13.72M--
Gross Profit
-¥ 7.99M¥ 13.72M--
Operating Expense
-¥ 101.23M¥ 110.46M¥ 191.66M¥ 113.29M
Operating Income
-¥ -101.23M¥ -110.46M¥ -191.66M¥ -113.29M
Net Non Operating Interest Income Expense
-¥ 10.71M¥ 98.00K¥ -2.18M¥ 1.01M
Other Income Expense
-¥ -924.00K¥ 102.78M¥ -585.39M¥ -56.35M
Pretax Income
-¥ -795.02M¥ -213.14M¥ -779.23M¥ -168.63M
Tax Provision
-¥ 2.00M¥ 1.70M¥ 0.00¥ 0.00
Earnings From Equity Interest Net Of Tax
-----
Net Income Common Stockholders
-¥ -124.55M¥ -214.84M¥ -779.23M¥ -168.63M
Basic EPS
-¥ -14.50¥ -25.00¥ -13.96¥ -3.02
Diluted EPS
-¥ -2.10-¥ -13.96¥ -3.02
Basic Average Shares
-¥ 55.04M¥ 52.18M¥ 55.82M¥ 55.82M
Diluted Average Shares
-¥ 59.31M-¥ 55.82M¥ 55.82M
Dividend Per Share
-----
Total Operating Income As Reported
-----
Reported Normalized Basic E P S
-----
Reported Normalized Diluted E P S
-----
Rent Expense Supplemental
-----
Total Expenses
-¥ 93.25M¥ 96.75M¥ 191.66M¥ 113.29M
Net Income From Continuing And Discontinued Operation
-¥ -124.55M¥ -214.84M¥ -779.23M¥ -168.63M
Normalized Income
---¥ -773.13M¥ -171.68M
Interest Expense
---¥ 42.00K¥ 53.00K
EBIT
-¥ -795.16M¥ -213.24M¥ -779.18M¥ -168.57M
EBITDA
-¥ -802.10M¥ -217.32M¥ -777.74M¥ -167.78M
Currency in CNY

Connect Biopharma Holdings Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis